Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GNC carding policy

This article was originally published in The Tan Sheet

Executive Summary

ID policy regarding products intended for adult users will encompass DHEA, kava, melatonin, synephrine, vincamine supplements, as well as ephedra, andro, GNC parent Royal Numico says. Also, GNC will "share best practices and recommendations with our vendors" following retailer's review of its own labeling practices to ensure labels provide clear information. GNC announced the initiatives Nov. 6 (1"The Tan Sheet" Nov. 11, 2002, p. 4)...

You may also be interested in...



GNC ID Policy Aimed At Halting Minors’ Purchases Of Ephedra

GNC will institute a nationwide identification policy in early 2003 for purchasers of products intended for use only by individuals over age 18, the Royal Numico division announced Nov. 6

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 

 

Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.

Topics

UsernamePublicRestriction

Register

PS094819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel